{"id":"W2501425081","doi":"10.1182/blood.v124.21.302.302","title":"Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Lenalidomide; Medicine; Dexamethasone; Regimen; Neutropenia; Multiple myeloma; Clinical endpoint; Internal medicine; Progressive disease; Phases of clinical research; Adverse effect; Gastroenterology; Dosing; Urology; Oncology; Toxicity; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003852788,0.002050429,0.00280336,0.0004864323,0.000612566,0.00166725,0.001350339,0.001433505,0.005747973],"category_scores_gemma":[0.001165139,0.0007440765,0.002399069,0.0005570111,0.0007789447,0.0008796398,0.0005844557,0.003066622,0.001785317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001888737,"about_ca_system_score_gemma":0.002887666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001510588,"about_ca_topic_score_gemma":0.004119977,"domain_scores_codex":[0.9985574,0.0006916049,0.00009361756,0.0002106411,0.0001731231,0.0002736693],"domain_scores_gemma":[0.999074,0.000118984,0.0001301586,0.00006111259,0.0001119492,0.0005037675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7029501,0.04568028,0.01890032,0.001556045,0.004384093,0.0005195786,0.0003788499,0.002925084,0.05040624,0.000611875,0.02294163,0.148746],"study_design_scores_gemma":[0.5762079,0.3665338,0.02874343,0.0001200587,0.001417215,0.0005349563,0.00006876326,0.0008420621,0.006478645,0.000402881,0.01857682,0.00007359625],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9238169,0.01629537,0.002589987,0.003177409,0.0006985179,0.02279624,0.02047245,0.0004557705,0.009697245],"genre_scores_gemma":[0.9409017,0.004197838,0.007750528,0.004516293,0.0004971059,0.01123918,0.02472559,0.0001491582,0.006022605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005747973,"threshold_uncertainty_score":0.02037573,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02640005774996663,"score_gpt":0.2912116139478415,"score_spread":0.2648115561978749,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}